MarketBeat
15 Nov 2026, 19:12 UTC · 1d ago
Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029
Impact · against what's priced in
Natera provides specific operational catalysts for 2027-2029, notably the timeline for the FIND colorectal cancer screening readout and the expected ASP increase for Signatera. The most immediate catalyst is the January pricing confirmation for the Japanese market launch.
- NTRA+0.40
No priced-in read yet
- In context
The market receives concrete timelines for the FIND colorectal cancer study (H2 2027 readout) and a specific target ASP increase to $1,450 by 2029, providing a clearer path to the $6 billion revenue goal.
Read from the article alone

- biotech
- healthcare
- NTRA
- cancer screening
- ceo transition
- diagnostics
- fda approval
- genetic testing
- japan market
- revenue guidance
Search tags




